Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...

James O'Reilly, 77, had served just over two-and-a-half years of a 20-year sentence when he died of lung cancer at the Midlands Prison, a new report shows ...